HIV treatment interruption study for long-term participants
Part of Infections clinical trials.
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been in a previous study that included a break from HIV meds (ATI).
- Your HIV was under control (viral load undetectable) for at least 24 weeks after starting the break.
- You are still off HIV meds and haven't had more than 4 weeks in a row with a viral load over 1000.
- Your CD4 count (a type of immune cell) is above 350 in the month before joining.
- You are willing to stay off meds for up to 96 weeks and restart meds if your doctor says it's needed.
- Women who can get pregnant must use effective birth control and agree to pregnancy testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if two lab-made antibodies can keep HIV under control when people temporarily stop their daily HIV medication. Participants will pause their antiretroviral therapy (ART) for a period and be closely monitored, with the goal of potentially finding a way to take a break from daily pills.
This study tests two drugs, baricitinib and sirolimus, alone or together, to see if they can help control HIV after you stop your usual HIV medications for a short time. The goal is to see if these drugs can keep the virus from rebounding.
This study looks at how the immune system and HIV behave in people on long-term HIV treatment (ART), using blood samples that will be stored for future tests for up to 20 years. It may help researchers understand how well treatment is controlling HIV and improve future care.
This study tests a new long-acting HIV medication taken by mouth that may allow you to switch from your current daily pill. It is for people who have had an undetectable HIV viral load for at least 6 months and are currently on a stable HIV treatment.
This study looks at a planned, supervised “treatment interruption” period for people with HIV who are very well controlled on HIV medicines. It mainly aims to understand what happens when therapy is paused and how to reduce the risk of passing HIV to others.
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.